Meet The Professor: Optimizing the Management of Multiple Myeloma

1

Introduction

00:00 • 3min

2

The Escopel Effect of Radiation in Multiple Myelom

02:40 • 2min

3

Do Checkpoint Inhibitors Really Work in Myeloma?

04:11 • 2min

4

The Difference Between Denisumab and Zolodronic Acid in Myeloma

05:58 • 2min

5

Bone Targeted Agents for Multiple Myeloma

07:31 • 2min

6

NOSAMAP vs DZolodronic Acid - What's the Bottom Line?

09:53 • 2min

7

Taking Care of Colleagues, Family Members, Etc.

12:23 • 2min

8

Is Dialysis an Option for an Elderly Patient With Renal Failure?

14:23 • 3min

9

Transplantation in an 80 Year Old?

17:29 • 2min

10

RVD Light With Darratumumab in Patients Without Renal Failure

19:02 • 2min

11

Is There a Role to Combine Lenalidomide With Darratumumab?

20:36 • 3min

12

Myeloma - A Case Study of a 62 Year Old Man With T4 14 and One Q 21 Edition

23:10 • 2min

13

Using CD38 Monochrome Antibody in a High Risk Patient Population

24:47 • 2min

14

Is Carfilzumib a Good Staging System?

26:50 • 2min

15

Carfilzumib vs Bortezamib

29:15 • 2min

16

Do I Need to Stop D.R.A.T.S?

31:34 • 5min

17

The Risk of Second Cancers in Leukemia After a Transplant?

36:24 • 2min

18

Is MRD a New Complete Response?

38:12 • 2min

19

CAR T Therapy in a 66 Year Old Female Quad Refractory Patient

40:39 • 2min

20

Do You Use Selenexar in Combination?

42:20 • 2min

21

BIS Specifics - Can It Be Done in the Community?

44:16 • 3min

22

CAR T Cells and BIS Specifics - What's Going to Happen?

47:00 • 2min

23

Is CAR T More Effective Than Silticell?

49:25 • 2min

24

Is It OK to Use Bellantimab?

51:32 • 2min

25

Isit Tuximab After Darrertumumab?

53:20 • 2min

26

Venetoclax for T1114 Translocations?

55:39 • 2min

27

Neuropathy

57:45 • 3min

Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series